According to a new systematic review and meta-analysis, new classes of antimigraine drugs appear to be effective and have improved tolerability among patients with chronic migraine.

Investigators compared the outcomes for acute migraine management using lasmiditan (a 5-hydroxytryptamine [5HT]1F–receptor agonist), and gepants - rimegepant and ubrogepant (calcitonin gene–related peptide [CGRP] antagonists) - with standard triptan (selective 5-HT1B/1D–receptor agonist) treatment. The analysis included 64 double-blind randomized clinical trials with 46,442 patients.

Virtually all medications with extensive clinical use were linked with higher ORs for freedom from pain when compared with placebo. In comparison with ditan and gepants, triptans were linked with significantly higher ORs for pain freedom, with the odds ratio ranges being 1.72-3.40 for lasmiditan, 1.58-3.13 for rimegepant, and 1.54-3.05 for ubrogepant. In terms of pain relief at 2 hours, triptans were found to be tied to higher ORs in comparison with other drug classes. The paper is published online in JAMA Network Open… (Medscape)